Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting - Seite 2

Forward-looking Statement 

This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “has the potential,” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our R&D programs. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2022 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. 

 For further information on Cellectis, please contact:  

Media contacts:     

Pascalyne Wilson, Director, Communications, [phone], [e-mail]

Patricia Sosa Navarro, Chief of Staff to the CEO, [phone], [e-mail]

Investor Relation contact:     

Ashley R. Robinson, LifeSci Advisors, [phone] 

Attachment

• ASGCT 2024-curtain raiser